Open

Coming up

Don't miss

Replay


LATEST SHOWS

WEB NEWS

Connected toys are a must-have for Christmas

Read more

WEB NEWS

Web users react to Cuba and the US normalizing relations

Read more

REPORTERS

Argentina: The Kirchner era

Read more

AFRICA NEWS

Tunisia presidential elections: Final day of campaigning ahead of Sunday's vote

Read more

FRANCE IN FOCUS

Holiday season: celebrating a secular Christmas

Read more

#THE 51%

Are toys really us?

Read more

ENCORE!

Child brides, the people of Syria and New York’s homeless

Read more

FOCUS

Video: Pakistan in mourning after school massacre

Read more

AFRICA NEWS

Kenya: Security law approved despite disruptions in Parliament

Read more

Sanofi-Aventis withdraws anti-obesity drug from European shelves

Text by AFP

Latest update : 2008-10-24

EU authorities have suspended sales of pharmaceutical giant Sanofi-Aventis' anti-obesity drug Acomplia across the continent, due to an abnormal risk of psychiatric problems.

EU authorities suspended sales of pharmaceutical giant Sanofi-Aventis' anti-obesity drug Acomplia across the continent Thursday, the firm announced, adding that it had not ruled out a worldwide halt.

"Sales have been halted in all the pharmacies in the 18 countries of the European Union where it is distributed," a company spokesman told AFP.

Sanofi-Aventis said the European Medicines Agency (EMEA) had warned that patients taking the drug ran almost double the normal risk of psychiatric problems.

"The risks of taking Acomplia are now greater than the benefits that the drug can bring the patient according to its current guidelines," the company said, citing the EMEA.

Europe has allowed sales of Acomplia since 2006, but it has not been authorised in the United States where authorities believe it encourages suicidal thoughts, even in patients with no history of depression.

The company said it had not ruled out withdrawing the drug in the 14 non-EU countries where it is sold. It said users of the drug should consult a doctor or pharmacist.
 

Date created : 2008-10-24

COMMENT(S)